{"data":[{"accessionNo":"0002073679-26-000066","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001880438","issuerName":"AN2 Therapeutics, Inc.","ticker":"ANTX","cusip":"037326105","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"Almitas Capital LLC","reportingCik":null,"personType":"IA","sharesOwned":1479129,"percentOfClass":4.1,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/antx"},{"accessionNo":"0001831942-26-000014","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001880438","issuerName":"AN2 Therapeutics, Inc.","ticker":"ANTX","cusip":"037326105","securityClass":"Common Stock, par value $0.00001 per share","eventDate":"2026-03-09","reportingPerson":"Robert Egen Atkinson","reportingCik":null,"personType":"IN,HC","sharesOwned":3697435,"percentOfClass":9.9,"filedAt":"2026-03-16","canonicalUrl":"https://xoomar.com/markets/stocks/antx"},{"accessionNo":"0001831942-26-000014","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001880438","issuerName":"AN2 Therapeutics, Inc.","ticker":"ANTX","cusip":"037326105","securityClass":"Common Stock, par value $0.00001 per share","eventDate":"2026-03-09","reportingPerson":"Michael Kramarz","reportingCik":null,"personType":"HC,IN","sharesOwned":3697435,"percentOfClass":9.9,"filedAt":"2026-03-16","canonicalUrl":"https://xoomar.com/markets/stocks/antx"},{"accessionNo":"0001831942-26-000014","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001880438","issuerName":"AN2 Therapeutics, Inc.","ticker":"ANTX","cusip":"037326105","securityClass":"Common Stock, par value $0.00001 per share","eventDate":"2026-03-09","reportingPerson":"Commodore Capital LP","reportingCik":null,"personType":"IA,PN","sharesOwned":3697435,"percentOfClass":9.9,"filedAt":"2026-03-16","canonicalUrl":"https://xoomar.com/markets/stocks/antx"},{"accessionNo":"0001831942-26-000014","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001880438","issuerName":"AN2 Therapeutics, Inc.","ticker":"ANTX","cusip":"037326105","securityClass":"Common Stock, par value $0.00001 per share","eventDate":"2026-03-09","reportingPerson":"Commodore Capital Master LP","reportingCik":null,"personType":"PN","sharesOwned":3697435,"percentOfClass":9.9,"filedAt":"2026-03-16","canonicalUrl":"https://xoomar.com/markets/stocks/antx"},{"accessionNo":"0001213900-26-027660","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001880438","issuerName":"AN2 Therapeutics, Inc.","ticker":"ANTX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share","eventDate":"2026-03-10","reportingPerson":"Vivo Opportunity Fund Holdings, L.P.","reportingCik":null,"personType":"PN","sharesOwned":2864346,"percentOfClass":8,"filedAt":"2026-03-13","canonicalUrl":"https://xoomar.com/markets/stocks/antx"},{"accessionNo":"0001213900-26-027660","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001880438","issuerName":"AN2 Therapeutics, Inc.","ticker":"ANTX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share","eventDate":"2026-03-10","reportingPerson":"Vivo Opportunity, LLC","reportingCik":null,"personType":"OO","sharesOwned":2864346,"percentOfClass":8,"filedAt":"2026-03-13","canonicalUrl":"https://xoomar.com/markets/stocks/antx"},{"accessionNo":"0001104659-26-027730","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001880438","issuerName":"AN2 Therapeutics, Inc.","ticker":"ANTX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share","eventDate":"2026-03-06","reportingPerson":"Israel A. Englander","reportingCik":null,"personType":"IN","sharesOwned":2237102,"percentOfClass":6.3,"filedAt":"2026-03-13","canonicalUrl":"https://xoomar.com/markets/stocks/antx"},{"accessionNo":"0001104659-26-027730","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001880438","issuerName":"AN2 Therapeutics, Inc.","ticker":"ANTX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share","eventDate":"2026-03-06","reportingPerson":"Millennium Management LLC","reportingCik":null,"personType":"OO","sharesOwned":2237102,"percentOfClass":6.3,"filedAt":"2026-03-13","canonicalUrl":"https://xoomar.com/markets/stocks/antx"},{"accessionNo":"0001104659-26-027730","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001880438","issuerName":"AN2 Therapeutics, Inc.","ticker":"ANTX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share","eventDate":"2026-03-06","reportingPerson":"Millennium Group Management LLC","reportingCik":null,"personType":"OO","sharesOwned":2237102,"percentOfClass":6.3,"filedAt":"2026-03-13","canonicalUrl":"https://xoomar.com/markets/stocks/antx"},{"accessionNo":"0001104659-26-027730","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001880438","issuerName":"AN2 Therapeutics, Inc.","ticker":"ANTX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share","eventDate":"2026-03-06","reportingPerson":"Integrated Core Strategies (US) LLC","reportingCik":null,"personType":"OO","sharesOwned":2135044,"percentOfClass":6,"filedAt":"2026-03-13","canonicalUrl":"https://xoomar.com/markets/stocks/antx"},{"accessionNo":"0001213900-26-027660","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001880438","issuerName":"AN2 Therapeutics, Inc.","ticker":"ANTX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share","eventDate":"2026-03-10","reportingPerson":"Vivo Opportunity Cayman Fund, L.P.","reportingCik":null,"personType":"PN","sharesOwned":289294,"percentOfClass":0.8,"filedAt":"2026-03-13","canonicalUrl":"https://xoomar.com/markets/stocks/antx"},{"accessionNo":"0001213900-26-027660","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001880438","issuerName":"AN2 Therapeutics, Inc.","ticker":"ANTX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share","eventDate":"2026-03-10","reportingPerson":"Vivo Opportunity Cayman, LLC","reportingCik":null,"personType":"OO","sharesOwned":289294,"percentOfClass":0.8,"filedAt":"2026-03-13","canonicalUrl":"https://xoomar.com/markets/stocks/antx"},{"accessionNo":"0001596468-26-000004","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001880438","issuerName":"AN2 Therapeutics, Inc.","ticker":"ANTX","cusip":null,"securityClass":"Common Stock and Warrants","eventDate":"2025-12-31","reportingPerson":"Almitas Capital LLC","reportingCik":null,"personType":"IA","sharesOwned":2975164,"percentOfClass":5.4,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/antx"},{"accessionNo":"0001193125-26-051535","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001880438","issuerName":"AN2 Therapeutics, Inc.","ticker":"ANTX","cusip":null,"securityClass":"Common Stock, par value $0.00001 per share","eventDate":"2025-12-31","reportingPerson":"Eric Easom","reportingCik":null,"personType":"IN","sharesOwned":2232004,"percentOfClass":7.9,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/antx"},{"accessionNo":"0001596468-25-000022","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001880438","issuerName":"AN2 Therapeutics, Inc.","ticker":"ANTX","cusip":null,"securityClass":"Common Stock and Warrants","eventDate":"2025-09-30","reportingPerson":"Almitas Capital LLC","reportingCik":null,"personType":"IA","sharesOwned":1428323,"percentOfClass":5.2,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/antx"}],"updatedAt":"2026-11-04T03:50:53.982Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/antx","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}